Retlirafusp alfa

Multispecific antibody

Also known as SHR-1701

Approvedregulatory verdict

Evidence outlook

Approved: Retlirafusp alfa with chemotherapy for first-line treatment of PD-L1-positive advanced... (China)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the US

Also approved (1)
China
  • Retlirafusp alfa with chemotherapy for first-line treatment of PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma
Product first approved 2026eutils.ncbi.nlm.nih.gov

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Gastric Cancer
NCT07677293 · Peking University
2026-06-26 – 2028-12-31 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05179239 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-02-26 – 2024-08-12 · Cervical Cancer
What this study did
Phase 2/3 (2)
Gastric Cancer
NCT05149807 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-01-26 – 2024-04-03 · Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
What this study did
Other / comorbidity
NCT04856787 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021-06-22 – 2024-04-17 · Metastatic Colorectal Cancer (mCRC)
What this study did
Phase 2 (55)
Gastric Cancer
NCT07464756 · The First Affiliated Hospital with Nanjing Medical University
2026-04-03 – 2030-07-31 · Gastric Adenocarcinoma
What this study did
NCT07904442 · Anhui Provincial Cancer Hospital
2026-11-20 – 2030-02-28 · Gastric Cancer (Diagnosis)
What this study did
NCT07311408 · Jingdong Zhang
2026-01-01 – 2029-12-01 · Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06881017 · China Medical University, China
2025-05-01 – 2029-11-01 · Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
What this study did
NCT07689851 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-07-01 – 2029-07-30 · Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07874425 · Fudan University
2026-10 – 2028-12 · Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07294664 · The First Affiliated Hospital of Zhengzhou University
2025-06-15 – 2028-07-15 · Advanced Gastric Cancer, SHR1701
What this study did
NCT07102901 · Jiangsu HengRui Medicine Co., Ltd.
2025-09-05 – 2027-12 · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05671822 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-03-14 – 2027-12 · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07567326 · Peking University Cancer Hospital & Institute
2026-07 – 2030-12 · Non Small Cell Lung Cancer
What this study did
NCT07619911 · Fudan University
2026-07 – 2030-12 · NSCLC Stage III, SHR-1701, Chemoradiotherapy
What this study did
NCT07175220 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-09 – 2028-10 · Locally Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT07550920 · Tianjin Medical University Cancer Institute and Hospital
2026-05-10 – 2028-01-30 · NSCLC
What this study did
NCT04937972 · Hunan Province Tumor Hospital
2021-07-01 – 2025-06-01 · Non-Small Cell Lung Cancer
What this study did
NCT04580498 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-10 – 2025-03-01 · Non-Small-Cell Lung Cancer
What this study did
NCT05177497 · Shanghai Chest Hospital
2022-01 – 2024-10 · NSCLC, Stage III
What this study did
NCT04560244 · Shandong Cancer Hospital and Institute
2020-09 – 2022-12 · Non-Small-Cell Lung Cancer
What this study did
NCT04974957 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021-08-30 – 2022-08-30 · Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
What this study did
NCT04699968 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-15 – 2021-11-15 · Non-Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT07728019 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-07-30 – 2031-12-31 · CRC (Colorectal Cancer)
What this study did
NCT07924332 · Qun Zhao
2026-11-30 – 2031-12-30 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07802288 · Tianjin Medical University Cancer Institute and Hospital
2026-09-30 – 2031-09-30 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07384234 · Ruijin Hospital
2026-04-24 – 2030-12-30 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07845565 · Tianjin Medical University Cancer Institute and Hospital
2026-11 – 2030-05 · Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT07503639 · Fudan University
2026-04 – 2030-04 · Locally Advanced Colorectal Cancer
What this study did
NCT07934927 · Sun Yat-sen University
2026-09-29 – 2029-12-31 · Melanoma, Immune Checkpoint Inhibitor
What this study did
NCT07815288 · Peking University Cancer Hospital & Institute
2026-09-30 – 2029-12-30 · Colorectal Adenocarcinoma Metastatic in the Liver
What this study did
NCT07797244 · Dai, Guanghai
2026-10-29 – 2029-10 · Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
What this study did
NCT07814859 · The First Affiliated Hospital of Zhengzhou University
2026-08-31 – 2029-08-31 · Pancreatic Cancer
What this study did
NCT07716111 · The First Affiliated Hospital with Nanjing Medical University
2026-07-16 – 2029-08-31 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07752550 · Harbin Medical University
2026-07-30 – 2029-07-30 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT07610629 · Henan Cancer Hospital
2026-05-05 – 2029-06-30 · Gastric Adenocarcinoma
What this study did
NCT07682376 · Harbin Medical University
2026-06-10 – 2029-05-30 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07663071 · Harbin Medical University
2026-05-27 – 2029-05-27 · Rectal Cancer Patients
What this study did
NCT07847710 · The First Affiliated Hospital with Nanjing Medical University
2026-09-30 – 2029-03-01 · Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
What this study did
NCT07451795 · Fudan University
2026-03-02 – 2028-12-31 · Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
What this study did
NCT07806110 · The First Hospital of Jilin University
2026-07-30 – 2028-12-31 · Pancreas Ductal Adenocarcinoma
What this study did
NCT07517653 · Shanghai Zhongshan Hospital
2026-04-01 – 2028-12-30 · Melanoma
What this study did
NCT07773363 · Tang-Du Hospital
2026-08-30 – 2028-12-30 · Pancreatic Cancer
What this study did
NCT07749859 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-08 – 2028-12 · Advanced Unresectable Hepatocellular Carcinoma
What this study did
NCT07618910 · Tang-Du Hospital
2026-05-30 – 2028-05-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07607210 · Hebei Medical University Fourth Hospital
2026-06-01 – 2028-03-31 · Siewert Type II Adenocarcinoma of the Esophagogastric Junction
What this study did
NCT07524374 · Zhigang Li
2026-03-15 – 2028-03-30 · ESCC
What this study did
NCT07478731 · Hong Qiu
2025-12-20 – 2027-12-31 · CRC (Colorectal Cancer)
What this study did
NCT07147088 · Fudan University
2025-09-01 – 2027-09-01 · Advanced Intrahepatic Cholangiocarcinoma
What this study did
NCT06679673 · Fudan University
2024-12 – 2026-12 · Colorectal Cancer Metastatic
What this study did
Phase 1/2 (8)
Non-Small Cell Lung Cancer
NCT05503888 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-10-01 – 2027-07-30 · Relapsed or Advanced Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07802184 · West China Hospital
2026-09-21 – 2029-05-01 · Metastatic Pancreatic Cancer
What this study did
NCT05896046 · Chinese PLA General Hospital
2023-06-14 – 2026-06-01 · Relapsed or Refractory Hodgkin Lymphoma
What this study did
NCT04407741 · Chinese PLA General Hospital
2020-09-01 – 2025-12-01 · Solid Tumor, Lymphoma
What this study did
NCT04856774 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021-06-01 – 2024-03-30 · Advanced Solid Tumors
What this study did
NCT05020925 · Jiangsu HengRui Medicine Co., Ltd.
2021-09 – 2024-02 · Nasopharyngeal Carcinoma
What this study did
NCT04679038 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-17 – 2023-10-01 · Solid Tumor
What this study did
NCT04624217 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-24 – 2023-02-08 · Pancreatic Cancer
What this study did
Phase 1 (7)
Other / comorbidity
NCT07581574 · The First Affiliated Hospital with Nanjing Medical University
2026-05-01 – 2029-05-31 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03774979 · Jiangsu HengRui Medicine Co., Ltd.
2019-01-24 – 2023-12 · Solid Tumor
What this study did
NCT05198817 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-02-22 – 2023-06-30 · Advanced Malignant Tumors
What this study did
NCT05048134 · Jiangsu HengRui Medicine Co., Ltd.
2021-10-25 – 2023-05-23 · Advanced Malignancies
What this study did
NCT04324814 · Atridia Pty Ltd.
2020-03-31 – 2023-02-01 · Advanced Solid Tumor
What this study did
NCT03710265 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-20 – 2022-12-31 · Solid Tumor
What this study did
NCT04282070 · Jiangsu HengRui Medicine Co., Ltd.
2020-03-27 – 2022-12-15 · Nasopharyngeal Carcinoma
What this study did
Early phase / not applicable (4)
Gastric Cancer
NCT07855757 · Zhejiang Cancer Hospital
2026-06-01 – 2028-06-30 · Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
What this study did
Other / comorbidity
NCT07769866 · RenJi Hospital
2026-09-01 – 2030-06-30 · Esophageal Squamous Cell Cancer
What this study did
NCT07493382 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2029-04-01 · GEJ Adenocarcinoma
What this study did
NCT06893887 · Nanjing Tianyinshan Hospital
2025-05-22 – 2028-12-15 · Hepatocellular Carcinoma(HCC)
What this study did

Competitive landscape

This drug's own stage for Gastric Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Retlirafusp Alfa: this drugPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signal
NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24).
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Reliable signal
NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4)
NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7)
TislelizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabApprovedMultispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ASP2138Phase 3Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 3Small moleculeProstaglandin E2 receptor 4 (EP4)Reliable signal
NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040.
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sonesitatug VedotinPhase 3Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
agenT-797Phase 2Cell therapyInvariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigennot yet gradedNo reviewed efficacy summary in this indication
GivastomigPhase 2Multispecific antibodyClaudin 18.2 (CLDN18.2) x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1904Phase 2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
ASP546C
Phase 1/2(overall)
Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
TAK-921Phase 1/2Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(50 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Retlirafusp alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (17)
March 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-03-30 · NCT07550920 · CT.gov ↗
What to watch
April 2027 (1)
Early phase / not applicableGEJ AdenocarcinomaNot yet recruiting
Est. primary completion 2027-04-01 · NCT07493382 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT07581574 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-05-30 · NCT07618910 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-07-15 · NCT07294664 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-30 · NCT05503888 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07814859 · CT.gov ↗
What to watch
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07716111 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Advanced Intrahepatic CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07147088 · CT.gov ↗
What to watch
Phase 2ESCCNot yet recruiting
Est. primary completion 2027-09-30 · NCT07524374 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular Carcinoma(HCC)Recruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07773363 · CT.gov ↗
What to watch
Phase 2CRC (Colorectal Cancer)Recruiting
Est. primary completion 2027-12-31 · NCT07478731 · CT.gov ↗
What to watch
Phase 2Pancreas Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT07806110 · CT.gov ↗
What to watch
Phase 2GC, GEJCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07817654 · CT.gov ↗
What to watch
2028 (20)
January 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-01-01 · NCT07311408 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant TherapyRecruiting
Est. primary completion 2028-03-01 · NCT07847710 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)Recruiting
Est. primary completion 2028-03-31 · NCT07451795 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Locally Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07503639 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Rectal Cancer PatientsActive not recruiting
Est. primary completion 2028-05-27 · NCT07663071 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Active not recruiting
Est. primary completion 2028-05-30 · NCT07682376 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-05-31 · NCT07464756 · CT.gov ↗
What to watch
June 2028 (1)
Early phase / not applicableGastric CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT07855757 · CT.gov ↗
What to watch
July 2028 (4)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07619911 · CT.gov ↗
What to watch
Phase 2Advanced Unresectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-07 · NCT07749859 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-07-30 · NCT07689851 · CT.gov ↗
What to watch
Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-07-30 · NCT07752550 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10 · NCT07175220 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-11-30 · NCT07517653 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07567326 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07874425 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07355010 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT07384234 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07610629 · CT.gov ↗
What to watch
Phase 3Gastric CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07677293 · CT.gov ↗
What to watch
2029 (13)
January 2029 (1)
Phase 1/2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2029-01-01 · NCT07802184 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Esophageal Cancer, ESCCNot yet recruiting
Est. primary completion 2029-03-01 · NCT07770672 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-03-30 · NCT07924332 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)Not yet recruiting
Est. primary completion 2029-04 · NCT07797244 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04-30 · NCT07802288 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2029-05 · NCT07845565 · CT.gov ↗
What to watch
June 2029 (3)
Phase 2CRC (Colorectal Cancer)Recruiting
Est. primary completion 2029-06-30 · NCT07728019 · CT.gov ↗
What to watch
Phase 2Valid MeSH ConditionsNot yet recruiting
Est. primary completion 2029-06-30 · NCT07709533 · CT.gov ↗
What to watch
Early phase / not applicableEsophageal Squamous Cell CancerNot yet recruiting
Est. primary completion 2029-06-30 · NCT07769866 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Colorectal Adenocarcinoma Metastatic in the LiverNot yet recruiting
Est. primary completion 2029-12-30 · NCT07815288 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07904442 · CT.gov ↗
What to watch
Phase 2Melanoma, Immune Checkpoint InhibitorRecruiting
Est. primary completion 2029-12-31 · NCT07934927 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 September 2026Topline resultRELIGHT Phase 3 (NCT04950322) met its overall survival primary endpoint (full results in JCO)
China · Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Source ↗